ReviewInfection and immunity2018
Novel Mechanism behind the Immunopathogenesis of Vulvovaginal Candidiasis: "Neutrophil Anergy".
Review in Infection and immunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Guideline
- Epidemiology, Diagnostics and Therapy of Vulvovaginal Fungal Infections.Pathogens (Basel, Switzerland) · 2026Review
- Cytokine signalling in vaginal epithelial cells: mechanistic insights into epithelial immunity and inflammatory milieu in vulvovaginal candidiasis.European cytokine network · 2026Review
- Saccharomyces cerevisiae reduces vulvovaginal candidiasis severity through modulation of fungal pathogenicity and inflammatory responses.Nature communications · 2026Article
- Devising a Zfu2p targeted antifungal strategy that may preserve commensalism while suppressing Candida albicans virulence during vulvovaginal candidiasis.Scientific reports · 2026Article
- Expression of Human CEACAM Receptors Promotes Inflammation and Organ Damage During SystemicCells · 2026Article
- Hemolytic Activity of VaginalPathogens (Basel, Switzerland) · 2026Article
- Characterization of the vaginal microbiome and its metabolic potential in Colombian patients with recurrent vulvovaginal candidiasis.Medical mycology · 2026Article
- Ferroptosis in Recurrent Vulvovaginal Candidiasis Through Integrated Bioinformatics and Experimental Validation.Antioxidants (Basel, Switzerland) · 2026Article
- Biphasic Regulation of Epithelial Antimicrobial Peptides DuringJournal of fungi (Basel, Switzerland) · 2026Article
- Dual effects of vaginal Candida albicans on human papillomavirus infection: A large-scale multicenter study in Chinese women.Journal of advanced research · 2026Article
- Article
- Lactic acid in the vaginal milieu modulates theVirulence · 2025Article
- Mucosal passive immunization with monoclonal antibodies targeting Candidalysin and Hyr proteins attenuates vaginal candidiasis in mice.Virulence · 2025Article
- Perspectives on Vaginal Ecology and Management of Recurrent Vulvovaginal Candidiasis: A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- The Role of TLR2/TLR4 Receptors in Host Genetic Susceptibility to Recurrent Vulvovaginitis.Journal of fungi (Basel, Switzerland) · 2025Review
- Probiotic Lactobacillus Species Modulate Immune Responses During Vaginal Epithelial Cell Colonization.The Journal of infectious diseases · 2025Article
- Through thick and thin: The vaginal microbiome as both occupant and healer.PLoS pathogens · 2025Article
- Vaginal mycobiome characteristics and therapeutic strategies in vulvovaginal candidiasis (VVC): differentiating pathogenic species and microecological features for stratified treatment.Clinical microbiology reviews · 2025Review
- Protective efficacy of the pan-fungal vaccine NXT-2 against vulvovaginal candidiasis in a murine model.NPJ vaccines · 2025Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
For over 3 decades, investigators have studied the pathogenesis of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC) through clinical studies and animal models. While there was considerable consensus that susceptibility was not associated with any apparent deficiencies in adaptive immunity, protective immune mechanisms and the role of innate immunity remained elusive. It was not until an innovative live-challenge design was conducted in women that a fuller understanding of the natural history of infection/disease was achieved. These studies revealed that symptomatic infection is associated with recruitment of polymorphonuclear neutrophils (PMNs) into the vaginal lumen. Subsequent studies in the established mouse model demonstrated that infiltrating PMNs were incapable of reducing the fungal burden, which supported the hypothesis that VVC/RVVC was an immunopathology, whereby
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.